Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside

Hims & Hers app and GLP-1 injection kit on a desk, highlighting weight-loss demand and HIMS stock focus. Key Points Shares of HIMS have plummeted 75% from their May 2025 highs, recently driven by a Novo Nordisk lawsuit filed on Feb. 9. The stock’s Relative Strength Index reading of 16.87 is absurdly low, suggesting it is oversold. Analysts are optimistic that a rebound is coming, with the average 12-month price target implying nearly 150% potential upside. Interested in Hims & Hers Health, Inc.? Here ...